DK

Coloplast to Donate $150,000 to Twin Cities Nonprofits Via New Community Engagement Program

Monday, August 2, 2021 - 2:00pm

Coloplast announced today that between now and December 2022 it is awarding $150,000 in grants to nonprofits in the Twin Cities.

Key Points: 
  • Coloplast announced today that between now and December 2022 it is awarding $150,000 in grants to nonprofits in the Twin Cities.
  • Coloplast is committed to being an active and meaningful participant in our local community, said Manu Varma, President at Coloplast.
  • We recognize there is a critical need in the Twin Cities, especially among underserved and underrepresented members of our BIPOC communities.
  • The new community engagement program includes two components: a strategic, year-long partnership with one local Twin Cities nonprofit and a new community grant program.

ALK and Grandpharma team up to market the first adrenaline autoinjector in China

Friday, July 30, 2021 - 1:51pm

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) to launch its adrenaline autoinjector (AAI), Jext, in China via a partnership with leading supplier of adrenaline, Grandpharma.

Key Points: 
  • ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) to launch its adrenaline autoinjector (AAI), Jext, in China via a partnership with leading supplier of adrenaline, Grandpharma.
  • ALK will receive upfront and registration milestone payments totalling EUR 12 million (~DKK 90 million) in return for granting Grandpharma the exclusive rights to Jext in China.
  • ALK will also manufacture and supply Jext and receive revenue from the sale of products to Grandpharma.
  • Grandpharma is the leading supplier of adrenaline ampoules in China today and the company has extensive commercial reach within clinics and emergency care.

Zealand Pharma A/S – Final Transactions Under Share Repurchase Program

Tuesday, July 27, 2021 - 9:05pm

The details for each transaction made under the share repurchase program are included as an appendix to this announcement.

Key Points: 
  • The details for each transaction made under the share repurchase program are included as an appendix to this announcement.
  • With the transactions stated above, Zealand owns a total of 218,410 shares with a nominal value of DKK 1 each as treasury shares, corresponding to 0.5% of the total share capital.
  • The total share capital of the company is DKK 43,541,838 with a nominal value of DKK 1 each.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines.

Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

Monday, July 26, 2021 - 7:30am

Hrsholm, Denmark and Dallas, TX, U.S.A. (July 26, 2021) Allarity Therapeutics A/S (Allarity) and Lantern Pharma Inc. (Lantern) today announced that they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full authority to manage and guide future clinical development and commercialization.

Key Points: 
  • Hrsholm, Denmark and Dallas, TX, U.S.A. (July 26, 2021) Allarity Therapeutics A/S (Allarity) and Lantern Pharma Inc. (Lantern) today announced that they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full authority to manage and guide future clinical development and commercialization.
  • The drug was originally developed by MGI Pharma (USA) and Eisai (Japan), through Phase 3 clinical trials.
  • Under the agreement, Lantern will purchase assets and reacquire global, exclusive rights to further develop and commercialize Irofulven, and Allarity will discontinue further involvement in the Irofulven program.
  • Lantern will also receive a license to utilize, in its sole discretion, Allaritys Irofulven DRP companion diagnostic in future clinical development and commercialization of the drug.

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity

Monday, July 26, 2021 - 7:00am

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO).

Key Points: 
  • Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO).
  • Saniona is proud to be pioneering a regulatory path forward for people living with HO, and we are thrilled to have received the first-ever FDA orphan drug designation in HO.
  • Wood Foundation and parent of a child living with hypothalamic obesity, commented, The recognition of the first orphan drug designation in hypothalamic obesity is a critical milestone for the HO community.
  • Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control.

Major Shareholder Announcement

Wednesday, July 21, 2021 - 5:58pm

Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer.

Key Points: 
  • Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer.
  • Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners.
  • The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.
  • This Company Announcement contains forward looking statements.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021

Wednesday, July 21, 2021 - 11:31am

Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.

Key Points: 
  • Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.
    Copenhagen, Denmark; July 21, 2021 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S.), as reported by Johnson & Johnson were USD 1,433 million in the second quarter of 2021.
  • Net trade sales were USD 770 million in the U.S. and USD 663 million in the rest of the world.
  • Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC formulations, under the exclusive worldwide license to Janssen Biotech, Inc. (Janssen) to develop, manufacture and commercialize daratumumab.
  • Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab.

Zealand Pharma A/S – Transaction Under Share Repurchase Program

Tuesday, July 20, 2021 - 9:05pm

Company announcement – No. 47 / 2021

Key Points: 
  • The details for each transaction made under the share repurchase program are included as an appendix to this announcement.
  • The total share capital of the company is DKK 43,541,838 with a nominal value of DKK 1 each.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

Delek Logistics Partners, LP to Host Second Quarter 2021 Conference Call on August 4

Wednesday, July 14, 2021 - 9:15pm

BRENTWOOD, Tenn., July 14, 2021 /PRNewswire/ --Delek Logistics Partners, LP (NYSE: DKL) ("Delek Logistics") today announced that the Partnership intends to issue a press release summarizing second quarter 2021 results after the U.S. stock market closes on Tuesday, August 3, 2021.

Key Points: 
  • BRENTWOOD, Tenn., July 14, 2021 /PRNewswire/ --Delek Logistics Partners, LP (NYSE: DKL) ("Delek Logistics") today announced that the Partnership intends to issue a press release summarizing second quarter 2021 results after the U.S. stock market closes on Tuesday, August 3, 2021.
  • A conference call to discuss second quarter 2021 results is scheduled to begin at 7:30 a.m. CT (8:30 a.m.
  • Investors may also wish to listen to Delek US Holdings, Inc.'s (NYSE: DK) ("Delek US") second quarter 2021 earnings conference call on Wednesday, August 4, 2021 at 8:30 a.m. CT (9:30 a.m.
  • Market trends and information disclosed by Delek US may be relevant to Delek Logistics, as it is a consolidated subsidiary of Delek US.

Delek US Holdings to Host Second Quarter 2021 Conference Call on August 4

Wednesday, July 14, 2021 - 9:15pm

BRENTWOOD, Tenn., July 14, 2021 /PRNewswire/ -- Delek US Holdings, Inc. (NYSE: DK) ("Delek US") today announced that the Company intends to issue a press release summarizing second quarter 2021 results after the U.S. stock market closes on Tuesday, August 3, 2021.

Key Points: 
  • BRENTWOOD, Tenn., July 14, 2021 /PRNewswire/ -- Delek US Holdings, Inc. (NYSE: DK) ("Delek US") today announced that the Company intends to issue a press release summarizing second quarter 2021 results after the U.S. stock market closes on Tuesday, August 3, 2021.
  • A conference call to discuss second quarter 2021 results is scheduled to begin at 8:30 a.m. CT (9:30 a.m.
  • Investors may also wish to listen to Delek Logistics Partners, LP's (NYSE: DKL) ("Delek Logistics") second quarter 2021 earnings conference call on Wednesday, August 4, 2021 at 7:30 a.m. CT (8:30 a.m.
  • Market trends and information disclosed by Delek Logistics may be relevant to the logistics segment reported by Delek US.